Search
Cardiolipin Biosynthesis CL(a-13:0/a-25:0/18:2(9Z,11Z)/a-17:0)[rac]
smpdb.ca/view/SMP0371328MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/a-25:0/18:2(9Z,11Z)/a-21:0)[rac]
smpdb.ca/view/SMP0371329MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/a-25:0/18:2(9Z,11Z)/a-25:0)[rac]
smpdb.ca/view/SMP0371330MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-17:0/18:2(9Z,11Z))[rac]
smpdb.ca/view/SMP0371380MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/a-25:0/a-25:0/18:2(9Z,11Z))[rac]
smpdb.ca/view/SMP0371417MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Orlistat
go.drugbank.com/drugs/DB01083ApprovedInvestigationalIt was approved by the FDA for use in combination with a reduced-calorie diet in 1999. … [A229928] Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersProducts: ORLISTAT EG, SLENDER 1Bicalutamide
go.drugbank.com/drugs/DB01128ApprovedInvestigationalBicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsProducts: BICALUTAMIDE EG, BICALUTAMIDE EG STADACardiolipin Biosynthesis CL(a-13:0/18:2(9Z,11Z)/a-13:0/a-17:0)[rac]
smpdb.ca/view/SMP0351532MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/18:2(9Z,11Z)/a-13:0/a-21:0)[rac]
smpdb.ca/view/SMP0351542MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(a-13:0/18:2(9Z,11Z)/a-15:0/a-13:0)[rac]
smpdb.ca/view/SMP0351642MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.